Message from the representative
Representative: SetoYasuyuki
(Director of National Cancer Center Hospital)
The ATLAS project was launched when the National Cancer Center Hospital was selected for the Japan Agency for Medical Research and Development (AMED)'s FY2 Clinical Research and Clinical Trial Promotion Research Program, "Project to Establish a Clinical Research and Clinical Trial Network in Asia."
Our hospital has been actively involved in international joint clinical trials in the Asian region to date, but the ATLAS project aims to establish a clinical trial infrastructure in major cancer research centers in ASEAN countries, particularly in Malaysia, Thailand, the Philippines, Indonesia, and Vietnam, and provide educational and training opportunities. In this way, we aim to build a platform for international joint clinical trials aimed at pharmaceutical approval under Japan's leadership, and for Asia to take the lead in global cancer treatment development.
This project aims to build a platform that can regularly conduct many international joint trials, while at the same time promoting the full-scale introduction of cancer genomic medicine in the Asian region. In addition, we plan to strengthen collaboration with Asian countries in many ways, such as through translational research in collaboration with Asian researchers and the expansion of the MASTER KEY project, an industry-academia collaborative development platform for rare cancers, to Asia.
To ensure the smooth implementation of the ATLAS project, close collaboration with the government, PMDA, AMED, pharmaceutical companies, patient groups, etc. is essential. We would like to sincerely appreciate your kind support and advice.
National Cancer Center Hospital
Director of a hospital Yasuyuki Seto
From the Director
Director: Yasuyuki Seto
(National Cancer Center Hospital)
The National Cancer Center Hospital has launched the ATLAS (Asian clinical TriaLs network for cAncerS) project to establish a clinical research network across Asia. This ATLAS project is funded by Japan Agency for Medical Research and Development (AMED).
While we have actively collaborated with Asian partners for international collaborative trials, under this project, we will further strengthen collaboration with ASEAN countries such as Malaysia, Thailand, the Philippines, Indonesia, and Vietnam, in particular, that have core cancer research centers. We will contribute to enhancing the research environment necessary for conducting clinical trials and will also provide capacity building programs for the clinical research professionals in the centers participating in this project. Through this initiative, we will build a platform where Japan will lead the international research collaborative targeting regulatory approval and create a position where Asia as a region will lead the world in drug development eventually.
For the success of the ATLAS project, it is indispensable to cooperate closely with multiple stakeholders, including the public sector, pharmaceutical companies, and patient advocates. We would appreciate in advance your continued support.
National Cancer Center Hospital
Director: Yasuyuki Seto
